ATE303135T1 - Pharmazeutische formulierungen zur gesteuerten freisetzung von 4-amino-6,7-dimethoxy-2-(5- - Google Patents

Pharmazeutische formulierungen zur gesteuerten freisetzung von 4-amino-6,7-dimethoxy-2-(5-

Info

Publication number
ATE303135T1
ATE303135T1 AT02775048T AT02775048T ATE303135T1 AT E303135 T1 ATE303135 T1 AT E303135T1 AT 02775048 T AT02775048 T AT 02775048T AT 02775048 T AT02775048 T AT 02775048T AT E303135 T1 ATE303135 T1 AT E303135T1
Authority
AT
Austria
Prior art keywords
dimethoxy
amino
controlled release
pharmaceutical formulations
formulations
Prior art date
Application number
AT02775048T
Other languages
English (en)
Inventor
John D Davis
Michael J Humphrey
Ross J Macrae
Janet S Smith
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Application granted granted Critical
Publication of ATE303135T1 publication Critical patent/ATE303135T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT02775048T 2001-10-11 2002-09-30 Pharmazeutische formulierungen zur gesteuerten freisetzung von 4-amino-6,7-dimethoxy-2-(5- ATE303135T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0124455.7A GB0124455D0 (en) 2001-10-11 2001-10-11 Pharmaceutical formulations
PCT/IB2002/004040 WO2003032956A1 (en) 2001-10-11 2002-09-30 Pharmaceutical formulations for the controlled release of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl) quinazoline

Publications (1)

Publication Number Publication Date
ATE303135T1 true ATE303135T1 (de) 2005-09-15

Family

ID=9923660

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02775048T ATE303135T1 (de) 2001-10-11 2002-09-30 Pharmazeutische formulierungen zur gesteuerten freisetzung von 4-amino-6,7-dimethoxy-2-(5-

Country Status (33)

Country Link
EP (1) EP1434570B8 (de)
JP (1) JP4131471B2 (de)
KR (1) KR20050032510A (de)
CN (1) CN1568180A (de)
AP (1) AP2004003001A0 (de)
AR (1) AR036782A1 (de)
AT (1) ATE303135T1 (de)
BR (1) BR0213196A (de)
CA (1) CA2461168A1 (de)
CO (1) CO5560534A2 (de)
DE (1) DE60205925T2 (de)
DK (1) DK1434570T3 (de)
DO (1) DOP2002000464A (de)
EA (1) EA006168B1 (de)
ES (1) ES2246017T3 (de)
GB (1) GB0124455D0 (de)
GT (1) GT200200184A (de)
HR (1) HRP20040261A2 (de)
HU (1) HUP0600064A3 (de)
IL (1) IL160969A0 (de)
IS (1) IS7179A (de)
MA (1) MA27075A1 (de)
MX (1) MXPA04003293A (de)
NO (1) NO20041520L (de)
OA (1) OA12709A (de)
PA (1) PA8556001A1 (de)
PE (1) PE20030551A1 (de)
PL (1) PL369666A1 (de)
PY (1) PY0223360A (de)
SV (1) SV2004001279A (de)
UY (1) UY27477A1 (de)
WO (1) WO2003032956A1 (de)
ZA (1) ZA200401976B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317663D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Pharmaceutical composition
AU2014240049C1 (en) 2013-03-14 2019-03-07 Amgen Inc. Heterocyclic compounds and their uses
KR101943592B1 (ko) 2017-08-31 2019-01-30 조현우 데이터 마이닝 기법을 이용한 전자가계부 시스템

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0466986B1 (de) * 1990-07-02 1994-04-27 Bend Research, Inc. Asymmetrische mikroporöse Kügelchen für regulierbare Freigabe
FR2752737B1 (fr) * 1996-08-29 1998-10-02 Synthelabo Comprime a liberation controlee de chlorhydrate d'alfuzosine
GB9700504D0 (en) * 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
IL141235A (en) * 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
WO2001064672A1 (en) * 2000-03-03 2001-09-07 Pfizer Limited 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline mesylat and polymorphs

Also Published As

Publication number Publication date
AP2004003001A0 (en) 2004-03-31
PE20030551A1 (es) 2003-06-26
OA12709A (en) 2006-06-26
EA200400431A1 (ru) 2004-08-26
EA006168B1 (ru) 2005-10-27
CA2461168A1 (en) 2003-04-24
AR036782A1 (es) 2004-10-06
IS7179A (is) 2004-03-11
NO20041520L (no) 2004-04-05
ES2246017T3 (es) 2006-02-01
HUP0600064A3 (en) 2007-02-28
HUP0600064A2 (en) 2006-06-28
MA27075A1 (fr) 2004-12-20
GT200200184A (es) 2003-05-23
WO2003032956A1 (en) 2003-04-24
HRP20040261A2 (en) 2004-08-31
PL369666A1 (en) 2005-05-02
UY27477A1 (es) 2003-05-30
EP1434570B1 (de) 2005-08-31
MXPA04003293A (es) 2004-07-23
BR0213196A (pt) 2004-08-31
IL160969A0 (en) 2004-08-31
DK1434570T3 (da) 2005-11-07
GB0124455D0 (en) 2001-12-05
JP2005507909A (ja) 2005-03-24
PY0223360A (es) 2004-04-01
KR20050032510A (ko) 2005-04-07
DE60205925T2 (de) 2006-06-08
CO5560534A2 (es) 2005-09-30
ZA200401976B (en) 2004-07-12
DOP2002000464A (es) 2003-04-15
EP1434570A1 (de) 2004-07-07
JP4131471B2 (ja) 2008-08-13
EP1434570B8 (de) 2005-10-26
SV2004001279A (es) 2004-02-19
CN1568180A (zh) 2005-01-19
PA8556001A1 (es) 2003-07-28
DE60205925D1 (de) 2005-10-06

Similar Documents

Publication Publication Date Title
DE60220661D1 (de) Transdermales pflaster zur verabreichung von fentanyl
DK1345910T3 (da) Quinazolinderivater, lægemidler indeholdende forbindelserne, deres anvendelse og fremgangsmåde til fremstilling deraf
NO20033556L (no) Farmasöytiske formuleringer
FI20011478L (fi) Farmaseuttinen koostumus
DE60213592D1 (de) Flüssige pharmazeutische zusammensetzung
DK1292594T3 (da) Quinazolinderivater til behandling af tumorer
DE60239648D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Asthma
DE60239554D1 (de) Medizinische vorrichtung zur abgabe von pflastern
DE60206889D1 (de) Pharmazeutische formulierung enthaltend bicalutamid
DE50206657D1 (de) Pharmazeutische zusammensetzung zur behandlung von multiple sklerose
DE60118859D1 (de) Pharmazeutische Zusammensetzung enthaltend Trehalose zur ophthalmischen Verwendung
DE60126838D1 (de) Amidoacetonitrile zur Bekämpfung von Endoparasiten
IS7691A (is) Lyfjasamsetningar til að meðhöndla æxli
DE60211183D1 (de) Pharmazeutische zusammensetzung enthaltend lumiracoxib
FI20022128A7 (fi) Farmaseuttinen koostumus
DE60217390D1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
DK1475379T3 (da) Anvendelse af scopinesterderivater til fremstilling af lægemidler
DE10291905D2 (de) Pharmazeutische Zusammensetzung
DE60227896D1 (de) Verfahen zur Herstellung von Polyalkylphenoxyaminoalkanen
DE60205925D1 (de) Pharmazeutische formulierungen zur gesteuerten freisetzung von 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisochinol-2-yl)-5-(2-pyridyl)chinazolin
ATE350029T1 (de) Pharmazeutische zusammensetzung enthaltend gamma- butyrobetain
DK1385512T3 (da) Anvendelse af pyridoindolonderivater til fremstilling af anticancerlægemidler
DE10107261B4 (de) Pharmazeutische Zusammensetzung
IT1338456B1 (it) Procedimento per la preparazione di alchiluree da o ,d-dimetil ditiocarbonato
EE200300563A (et) Bensüülaminopürimidiiniühendid, nende kasutamine ja ravim

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1434570

Country of ref document: EP

REN Ceased due to non-payment of the annual fee